Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Jedd D WolchokVanna Chiarion-SileniPiotr RutkowskiC Lance CoweyDirk SchadendorfJohn WagstaffPaola QueiroloReinhard DummerMarcus O ButlerAndrew G HillMichael A PostowCaroline Gaudy-MarquesteTheresa MedinaChristopher D LaoJohn WalkerIván Márquez-RodasJohn B A G HaanenMassimo GuidoboniMichele MaioPatrick SchöffskiMatteo S CarlinoShahneen SandhuCéleste LebbéPaolo Antonio AsciertoGeorgina V LongCorey RitchingsAyman NassarMargarita AskelsonMelanie Pe BenitoWenjia WangF Stephen HodiJames Larkinnull nullPublished in: The New England journal of medicine (2024)
The final trial results showed a continued, ongoing survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma. (Funded by Bristol Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).